Research Updates and Statements

05.11.2021

Pfizer’s Novel Prediction Model, Derived from Machine Learning, Shows Robust Performance for Identifying Heart Failure Patients At-Risk for Wild-Type Transthyretin Amyloid Cardiomyopathy, a Rare and Life-Threatening Condition

02.17.2021

In Vitro Study Published in The New England Journal of Medicine Demonstrates Sera from Individuals Immunized with the Pfizer- BioNTech COVID-19 Vaccine Neutralize SARS-CoV-2 with South African Variant Spike Mutations

02.08.2021

Pfizer and BioNTech Publish Data from In Vitro Studies in Nature Medicine Demonstrating COVID-19 Vaccine Elicits Antibodies that Neutralize SARS-CoV-2 with Key Mutations Present in U.K. and South African Variants

02.01.2021

Pfizer and BioNTech Publish Preclinical Data from Investigational COVID-19 Vaccine Program in Nature

01.29.2021

Pfizer and BioNTech Publish Data on COVID-19 Vaccine-Induced Antibodies’ Ability to Neutralize SARS-CoV-2 U.K. Strain Pseudovirus in Cell Culture in Science

12.15.2020

Pfizer Doses First Participants as Part of Global Achondroplasia Phase 2 Development Program

12.15.2020

Pfizer Doses First Participants as Part of Global Achondroplasia Phase 2 Development Program

07.22.2020

Pfizer Shares Pre-Clinical Data Updates on COVID-19 Antiviral Research Program

06.23.2020

NEW DATA ON THE BURDEN OF EMERGING S. PNEUMONIAE SEROTYPES PUBLISHED IN ISPPD 2020 ONLINE DIGITAL LIBRARY